Led · Equity · Jun 2025

PreciseDx develops PreciseBreast, an AI-enabled diagnostic that uses the company’s OncoIntelligence platform to inform breast cancer care. PreciseBreast combines seven morphologic features and four clinical factors into a single OncoIntelligence Score (0–100) to stratify recurrence risk and support care planning within hours. The test has been clinically validated in more than 3,000 breast cancer cases to reliably separate patients into two cohorts based on six‑year recurrence risk. The company says the platform could extend to treatment guidance for other solid tumor types. PreciseDx announced an $11 million financing, bringing total funding to over $43 million, to support ongoing clinical data collection, commercial expansion and planning for a 2026 commercial launch. The company also announced two executive hires: Eric Converse as CEO and Ed Sitar as CFO; founder Carlos Cordon‑Cardo retains a financial interest. PreciseDx is an NYC-based innovator in oncology diagnostics that leverages artificial intelligence for morphology-driven disease analysis. Its platform combines AI with the patented Morphology Feature Array® (MFA) to generate actionable intelligence for decision-making across the cancer care continuum. The company's flagship offering is PreciseBreast™, a risk assessment intended to inform breast cancer care and screening decisions. PreciseDx plans to use new funding to expand commercialization of PreciseBreast™. Financially, PreciseDx recently closed a $20.7M Series B to support those commercialization efforts. The company has completed analytical and clinical validation studies, received CLIA Standard approval and CLEP NYSDOH review for PreciseBreast™, and had a Cost Impact Study published in the Journal of Medical Economics. PreciseDx has added collaborations with UCLA, COTA, Baptist Health South Florida, and Baylor Scott & White Health.

Led · Series A · Sep 2023

IOMED develops AI-powered technology to activate healthcare data across hospitals, unlocking both structured and unstructured sources via a Natural Language Processing system. Its platform transforms data into the OMOP Common Data Model and keeps data inside hospital facilities using a Federated Data Model. The company positions itself as a strategic ally for real-world data–driven healthcare ecosystems and says its mission is to drive a better future for healthcare through AI. IOMED plans international expansion and to consolidate its market position as part of this next growth stage. It has recently strengthened its business and technology leadership team and updated its brand image to reflect its maturity and innovation. Financially, IOMED closed a €10 million Series A and received a nearly €1 million grant from red.es for an AI R&D project. IOMED builds AI and natural language processing software that transforms free-text electronic health records into coded, structured data for clinical research. Its product suite includes locally installed GDPR-compliant data storage, software for observational studies, and a patient-matching network for clinical trials. The company currently works with hospitals across Spain, running projects in 27 medical centres including Vall d'Hebron, Hospital del Mar and Cruces-Biocruces Bizkaia University Hospital. IOMED plans to expand throughout Spain and into Germany and the UK using proceeds from its latest raise. It raised €2 million in the most recent funding round. The startup was founded in 2016 by Álvaro Abella, Gabriel de Maeztu and Javier de Oca and is based in Barcelona. IOMED Medical Solutions develops Medical Language API (MEL), a software that uses natural-language understanding to extract clinically relevant concepts from physicians' electronic records and store them in structured databases. MEL launched to market in 2017 and the company operates under the umbrella of IQS Tech Factory, Spain's first industrial startup accelerator. IOMED applies big‑data analytics to the structured outputs to build predictive models for clinical events such as future hospital readmissions. The technology began implementation in the traumatology area of Hospital Universitario Vall d’Hebron in 2018. The company closed a €500,000 financing round in 2018 that will be used to expand its team and broaden deployment of its technology into new areas. IOMED positions its solution as a way for hospitals to anticipate events, improve patient care and generate operational efficiencies.

Participated · Series A · Jul 2022

Moving Analytics (Movn) offers a 12-week, data-driven at-home cardiac rehabilitation program that provides patients with a cellular-enabled scale, Bodytrace blood pressure cuff, Garmin fitness tracker, exercise bands and an American Heart Association information book. The company operates as a healthcare provider and contracts with payers including Kaiser Permanente, Allegheny Health Network and CDPHP, running operations in 14 states and serving approximately 4,000 patients. Movn reports large improvements in enrollment and completion rates with partners (for example, Kaiser completion improved from 14% to 88%) and positions its program as a cheaper alternative to in-person sessions. The founders — Harsh Vathsangam, Shuo Qiao and Ade Adesanya — built the offering around a clinician-supported, empathy-focused intervention. Financially, the company has raised a total of $30 million to date and just closed a $20 million Series A. Planned uses for the new capital include expanding coverage to all 50 states, hiring staff and launching bilingual programming to better serve marginalized communities. Moving Analytics offers Movn, a virtual cardiac rehabilitation and cardiovascular disease management program developed in partnership with Stanford and grounded in more than 30 years of published research involving over 70,000 patients. The company’s flagship Movn product targets patients after acute coronary events and has been deployed with customers such as Kaiser Permanente, Highmark Health, Allegheny Health Network and the Veteran Affairs. Moving Analytics says it has served several thousand patients and cites Highmark results showing over a 60% enrollment rate, an 80% completion rate and equivalent clinical outcomes. The company will use the new funding to expand the Movn program, grow its partner and customer base, enroll more patients and improve the patient experience with richer, more tailored educational content. Moving Analytics also plans to expand into more markets and ensure its programs meet Medicare reimbursement requirements to support future growth. Financially, the company raised $6M in a Series Seed-2 and has received $9.5M in total funding to date; the round was led by Aphelion Capital through Cardeation Capital with co-investments from OCA Ventures and Seae Ventures. Moving Analytics provides Movn, a technology-enabled, home-based cardiac rehab program based on MULTIFIT, an evidence-based protocol developed at Stanford. The app generates individualized care plans, guides patients through supervised exercises, delivers educational content, tracks vital signs, enables provider chat, analyzes patient behavior, and alerts care managers to issues. Care managers coach patients with weekly phone-based sessions and modify treatment plans based on symptoms and progress. Movn has been validated on over 70,000 patients and is being used in hospitals including NYU Langone Medical Center, Our Lady of Lourdes, and the Atlanta Veterans Affairs Medical Center. The company said it will use the new capital to expand sales and marketing and to roll the product out into additional locations with existing customers. Moving Analytics is led by CEO and founder Harsh Vathsangam. Moving Analytics is a digital health company offering a home-based cardiac rehab solution hospitals can deploy for patients to do at home. Its cardiac rehab program, developed by researchers at Stanford University, includes evidence-based clinical protocols, a chronic care management system, a patient mobile application and implementation support. The company will use the $1.1M funding to expand its cardiac rehab product into the U.S. market and to further develop a home-based COPD product to complement its offerings. The $1.1M round was led by Launchpad Digital Health with participation from HealthX Ventures. Moving Analytics is led by CEO and founder Harshvardhan Vathsangam and is based in Marina Del Rey, California; it is participating in Launchpad Digital Health’s one-year accelerator in San Francisco. Its clients include medical institutions across the U.S., including California, New York, New Jersey, Florida and Georgia.

Participated · Series C · Dec 2021

Suki offers Suki Assistant, a generative-AI clinical assistant that ambiently listens to patient‑clinician conversations to create documentation, assist with coding, answer medical questions, and retrieve chart data. The company also licenses Suki Platform to partners who want to add ambient and voice AI capabilities to their products. Suki reports usage at 350 health systems and clinics and says clinicians complete notes 72% faster on average; the company claims a 9X ROI in year one for organizations. In 2024 Suki expanded 4x in 12 months and has been scaling technology, partnerships, and headcount to support further growth. Recent platform partnerships include Zoom (Workplace for Clinicians) and Google Cloud (Vertex AI integration) to add patient summaries, Q&A, and other features that speed clinical decision‑making. The company has added senior hires in marketing, legal, and infrastructure as part of this growth phase. Suki is positioned to deepen integrations with major EHR and healthcare technology partners such as Epic, athenahealth, MEDITECH, and others. Suki builds AI voice solutions for healthcare, notably Suki Assistant—an ambient, generative‑AI clinical documentation assistant—and Suki Platform, a suite of developer tools for embedding AI and voice into healthtech products. Suki Assistant ambiently generates notes, supports dictation and commands, simplifies coding, retrieves live EHR chart data, and incorporates vitals and pre‑charting into notes. The company reports industry‑leading metrics: 70+ percent clinician adoption, note completion up to 72% faster, and a reported 9X ROI in year one. Suki has expanded partnerships with major EHRs and health systems, including Epic, Oracle Cerner, MEDITECH, Athena, MedStar Health and more than a dozen major health systems and hospitals recently. The company will use the new capital to invest in commercial initiatives, accelerate product development, expand its leadership team, and broaden offerings beyond its existing Assistant and Platform products. Suki says its products augment clinician workflows, improve documentation quality and clinician well‑being, and enhance revenue capture for health systems. Suki.AI develops Suki Assistant, a voice-enabled digital assistant, and the Suki Speech Platform, using natural language processing and machine learning to generate clinically accurate medical notes and retrieve patient information from electronic health records. The company supports physicians across specialties including cardiology, orthopaedics, plastic surgery, ophthalmology, pediatrics and family medicine. Suki claims to reduce documentation time by 76% on average. The fresh funding will be used for strategic investments to advance the AI capabilities of its assistant and speech platform and to add features that streamline documentation, coding and other administrative tasks. Suki reported that it quadrupled its revenue in the last year. The company was founded in 2017 by Punit Singh Soni, who is the CEO.

Participated · Series C · Dec 2021

Suki offers Suki Assistant, an AI assistant that ambiently generates clinical notes, takes dictation and commands, simplifies coding, and retrieves relevant chart data from the EHR to answer clinical questions. Its Suki Platform provides developer tools used by EHRs, telehealth companies, and clinical communications firms to build AI voice experiences with minimal development effort. The company reports industry-leading adoption—over a 70% adoption rate—and health systems see note completion up to 72% faster while improving documentation quality and clinician well-being. Suki’s products integrate with major EHRs and health system partners, including Epic, Oracle Cerner, MEDITECH, Athena, and a multi-year collaboration with MedStar Health. The company has expanded rapidly, with over a dozen major health systems deploying or expanding access in recent months. Suki plans to expand beyond its existing offerings, deepen strategic partnerships, accelerate product development, and grow its commercial and leadership teams using the new capital. Suki builds AI-powered voice solutions for healthcare, with its flagship Suki Assistant that creates clinically accurate medical notes and streamlines tasks like EHR retrieval and ICD-10 coding. The company also offers a proprietary voice platform referenced in the release as Suki Speech Platform / Suki Speech Service. Suki says its solution reduces documentation time by 76% on average and is used by physicians across dozens of specialties in more than 90 health systems and clinics nationwide. Over the last year the company quadrupled its revenue and introduced capabilities such as dynamic EHR data pulling and a Windows app to expand device reach. Suki has refined its ICD-10 coding features and continues expanding beyond core clinical documentation. The company plans to use new capital to grow its user base via partnerships with health systems and medical groups, hire and develop employees, and advance the AI capabilities of Suki Assistant and its voice platform. Suki provides a voice-enabled digital clinical assistant that uses natural language processing and machine learning to create clinically accurate medical notes and complete administrative tasks like retrieving patient information from electronic health records. Across its user base, Suki lowered physicians' average time per note from more than 13 minutes to just over 3 minutes (a 76% reduction) and has been shown to decrease claims denial rates by up to 19% by generating highly detailed clinical documentation. The product supports physicians in any clinical setting and across specialties including cardiology, orthopedics, plastic surgery, ophthalmology, pediatrics, and family medicine. Suki plans to expand its user base through new and existing partnerships with leading health systems and medical groups and to advance its AI capabilities while adding features that streamline documentation, coding, billing, and other administrative tasks. The company has recently grown its team with hires including Jallel Harrati as vice president of sales and Jatin Chhugani as vice president of engineering. Suki, founded by Punit Soni, is developing a voice-based digital assistant that lets doctors dictate clinical notes and have them captured and pushed into underlying electronic medical record systems. The company emphasizes relieving physician burnout by simplifying documentation workflows across exam-room interfaces like iOS apps and web. Suki relies on commoditized voice recognition and focuses on the harder problem of understanding clinical language and mapping utterances into structured patient documentation. The product must adapt to individual doctors’ documentation styles and improve over time as it collects more data, which the company sees as a path to defensibility. The team changed its name from Robin AI to Suki because the new wake word is better suited for a voice assistant in the clinic. To date the company has raised roughly $20 million in total funding.